Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06284434
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-02-21
Brief Title:
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
Sponsor:
Kerry ORourke
Organization:
Shriners Hospitals for Children
Study Overview
Official Title:
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn if a pain medication called liposomal bupivacaine brand name EXPAREL with epinephrine will provide better pain control increased activity and reduced use of opioids compared with the standard treatment for patients age 6 years and older with cleft lip and palate who have had an alveolar bone graft surgery Investigators will look at
pain scores at hip and jaw sites
opioid use in amount and frequency
scores on activity questionnaires Researchers will compare the results of these items with those of patients who had the standard treatment of bupivacaine with epinephrine
pain scores at hip and jaw sites
opioid use in amount and frequency
scores on activity questionnaires Researchers will compare the results of these items with those of patients who had the standard treatment of bupivacaine with epinephrine
Detailed Description:
The study is a randomized double-blinded trial comparing liposomal bupivacaine EXPAREL with epinephrine 025 local anesthetic with the standard treatment of bupivacaine with epinephrine 025 local anesthetic The study will enroll patients with cleft lip and palate undergoing an alveolar bone graft ABG surgery Researchers will enroll a maximum of 60 patients from Shriners Childrens Chicago over a 2-year period
After this surgery patients experience significant pain Considering both the frequency of reported pain after ABG combined with the current opioid crisis and subsequent recommendations by organizations such as the American Society of Anesthesiologists Task Force on Acute Pain Management and Guidelines from the Society for Pediatric Anesthesia for alternative pain management the use of liposomal bupivacaine EXPAREL is a potential alternative to reduce post-operative pain in the pediatric ABG population
Liposomal bupivacaine LB is an injectable form of bupivacaine used at the surgical site and that is released over time Studies have shown that LB better controls pain especially during the first 24 hours post-surgery Better pain control has been associated with a reduction in opioid usage and its associated complications
The study is designed to randomize patients to either the standard of care bupivacaine with epinephrine or liposomal bupivacaine with epinephrine to better study pain management within the first five days after ABG surgery in Shriners cleft lip and palate patients
The FDA approved EXPAREL for the adult population in 2011 and for the pediatric population age 6 years and older in 2021 It is a locally injected single dose analgesia that is released over 72 hours
The study is considered minimal risk because LB use does not present an increased risk over the standard of care standard bupivacaine as it is an alternative form of the same pain medication Previous studies have shown no additional risk to using the liposomal version of bupivacaine vs standard bupivacaine in ABG surgeries
Patients will participate up to 5 days following surgery surgery day is considered day 0 with reported pain activity scores and opioid use collected through either paper electronic or phone questionnaires Surgeons and patients will be unaware of which cohort the patient will be randomized to be part of The pharmacist anesthesiologist and research coordinator may all be aware of which drug is administered
Researchers will obtain informed consent from the participants andor their legally authorized representatives before surgery
After this surgery patients experience significant pain Considering both the frequency of reported pain after ABG combined with the current opioid crisis and subsequent recommendations by organizations such as the American Society of Anesthesiologists Task Force on Acute Pain Management and Guidelines from the Society for Pediatric Anesthesia for alternative pain management the use of liposomal bupivacaine EXPAREL is a potential alternative to reduce post-operative pain in the pediatric ABG population
Liposomal bupivacaine LB is an injectable form of bupivacaine used at the surgical site and that is released over time Studies have shown that LB better controls pain especially during the first 24 hours post-surgery Better pain control has been associated with a reduction in opioid usage and its associated complications
The study is designed to randomize patients to either the standard of care bupivacaine with epinephrine or liposomal bupivacaine with epinephrine to better study pain management within the first five days after ABG surgery in Shriners cleft lip and palate patients
The FDA approved EXPAREL for the adult population in 2011 and for the pediatric population age 6 years and older in 2021 It is a locally injected single dose analgesia that is released over 72 hours
The study is considered minimal risk because LB use does not present an increased risk over the standard of care standard bupivacaine as it is an alternative form of the same pain medication Previous studies have shown no additional risk to using the liposomal version of bupivacaine vs standard bupivacaine in ABG surgeries
Patients will participate up to 5 days following surgery surgery day is considered day 0 with reported pain activity scores and opioid use collected through either paper electronic or phone questionnaires Surgeons and patients will be unaware of which cohort the patient will be randomized to be part of The pharmacist anesthesiologist and research coordinator may all be aware of which drug is administered
Researchers will obtain informed consent from the participants andor their legally authorized representatives before surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None